However, today’s news from the Shenzhen Special Economic Zone has aroused the market’s attention. According to the media report, Smol Technology is cooperating with American pharmaceutical companies to develop inhalation therapy for new coronary pneumonia. Studies have shown that the inhaled therapy can reduce the production of the new coronavirus infectious virus by 90%.
Shi Zhiqiang, chief scientist and global R&D director of Smol Technology, said that he is maintaining close cooperation with AIM, a listed pharmaceutical company in the United States, to provide a safe atomization inhalation device for its drug Ampligen, and to jointly explore atomization technology in the treatment of new coronary pneumonia, etc. applications in the medical field. At present, the cooperation has entered the clinical research stage.
According to relevant information, AIM is an immunopharmaceutical company dedicated to the research and development of drugs for the treatment of various cancers, immune disorders and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.
Electronic cigarette supervision tends to be stricter, and atomization leaders are deployed in the medical field
At the same time, in recent years, the regulatory environment for electronic cigarettes has become stricter. For example, the State Tobacco Monopoly Administration recently issued the “Measures for the Administration of Electronic Cigarettes”, which mentioned that for the first time, it is clear that “the sale of flavored electronic cigarettes other than tobacco flavors is prohibited; “E-cigarette products sold” and other terms, review and qualify for existing companies and operators, and review and supervise in accordance with the rules and regulations of traditional tobacco.
The release of this policy has all affected the development of the electronic cigarette industry. Smol previously stated that the application of electronic atomization technology and products to the healthcare industry. Atomization technology is not only limited to electronic cigarettes, it also has broad prospects in medical and adjuvant therapy.
In fact, Smol has reached a cooperation as early as April 1, 2020, and has carried out in-depth research on how to use aerosol inhalation device to aerosolize the drug Ampligen to treat new coronary pneumonia. In addition, Small expects that these areas will become its future growth drivers.